FindTrial
Sign In

A phase II dose-ranging study of SYR-472

A phase II dose-ranging study of SYR-472

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220868
Enrollment
Unknown
Registered
2009-09-19
Start date
2009-09-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

investigational material(s) Generic name etc : SYR-472 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.The subject is an outpatient during the screening period. 2.The subject signs a written, informed consent form prior to the initiation of any study procedure., etc.

Exclusion criteria

Exclusion criteria: 1.The subject with serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease. 2.The subject who is considered ineligible to participate in the study by the investigator or subinvestigator. etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026